<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00517673</url>
  </required_header>
  <id_info>
    <org_study_id>BTI107248</org_study_id>
    <nct_id>NCT00517673</nct_id>
  </id_info>
  <brief_title>To Evaluate Safety, Tolerability, Pharmacokinetics, And Food Effect Of Single Doses Of GSK945237 In Healthy Subjects</brief_title>
  <official_title>A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of GSK945237 and the Effect of Food on Single Oral Doses of GSK945237 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK945237 is the first molecule of a new chemical class that is being developed for treatment
      of respiratory tract and other infections such as skin and soft tissue. This study drug has
      been tested in animals but has never been given to humans. This is a two part study. The
      purpose of the first part is to study the side effects of this drug in humans, and to study
      how much of the drug gets absorbed in the blood stream The second part of this study will
      compare absorption of the study drug in the blood stream when given with food and when given
      under fasting conditions
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Day 1 to follow-up visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Day 1 to Day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Infections, Bacterial</condition>
  <arm_group>
    <arm_group_label>GSK945237</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Study Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK945237</intervention_name>
    <arm_group_label>GSK945237</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female adults between 18 and 60 years of age.

          -  Body weight proportional to height.

          -  Female subjects must be of non-childbearing potential.

          -  QTc less than 450 msec at screening

        Exclusion Criteria:

          -  Any clinically relevant abnormality identified on the screening history and physical,
             or on laboratory evaluations or the 12-lead surface electrocardiogram at screening or
             pre-dose.

          -  A positive pre-study alcohol/urine drug screen.

          -  Use of nicotine-containing products.

          -  A positive pre-study HIV antibody, Hepatitis B surface antigen (HBsAg) or Hepatitis C
             antibody result.

          -  Recent participation in another study, use of certain medications, consumption certain
             fruits, juices, or red wine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2007</study_first_submitted>
  <study_first_submitted_qc>August 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2007</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

